627. Deputy Pádraig O'Sullivan asked the Minister for Health if a company (details supplied) has engaged with her Department, the HSE or the national centre for pharmacoeconomics regarding reimbursement of ojemda (tovorafenib) in Ireland; whether a reimbursement application has been submitted by the company; if so, the status of that application; if not, whether discussions have taken place with the company regarding…
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Pádraig O'Sullivan under the heading Medicinal Products.
75 questions match, newest first.
186. Deputy Pádraig O'Sullivan asked the Minister for Health if a drug (details supplied) is currently available for reimbursement to eligible patients in Ireland; the current status and outcome of its assessment for reimbursement; whether Irish residents receiving clinically indicated cancer treatment in Northern Ireland can have the cost of the drug covered by the State where the medicine is not reimbursed in Irela…
1178. Deputy Pádraig O'Sullivan asked the Minister for Health the average length of time between European Medicines Agency approval and reimbursement approval in Ireland for rare disease and orphan medicines; and the way in which this compares with other EU countries. [64549/26]
368. Deputy Pádraig O'Sullivan asked the Minister for Health the steps being taken to address the shortage of bumetanide, which has been in short supply since early May 2026 with an expected return date of the end of the year; the interim arrangements in place to protect patients with heart failure who depend on this medicine; and if she will make a statement on the matter. [53753/26]
369. Deputy Pádraig O'Sullivan asked the Minister for Health whether she will bring forward legislative proposals to permit therapeutic substitution by pharmacists during medicine shortages; and if she will make a statement on the matter. [53754/26]
851. Deputy Pádraig O'Sullivan asked the Minister for Health the number of patients availing of the GMS medicines optimisation support service since its commencement on 1 June 2026; the number of patients previously in receipt of phased dispensing who have transitioned to the new service; and if she will make a statement on the matter. [53324/26]
852. Deputy Pádraig O'Sullivan asked the Minister for Health the projected full-year cost of the GMS medicines optimisation support service, including the €0.35 fee payable per GMS item dispensed and the €32.50 monthly enhanced medicines optimisation support fee, as agreed under the Community Pharmacy Agreement 2025; the amount paid out under each fee to date in 2026; and if she will make a statement on the matter. […
853. Deputy Pádraig O'Sullivan asked the Minister for Health if she will publish the PCRS-approved list of medicines that qualify a patient for the enhanced medicines optimisation support fee under the GMS medicines optimisation support service; the clinical criteria used to compile that list; whether the list will be kept under review; and if she will make a statement on the matter. [53326/26]
854. Deputy Pádraig O'Sullivan asked the Minister for Health the eligibility criteria applying to the GMS medicines optimisation support service for patients with cognitive or physical impairment, intellectual disability, or experiencing social exclusion including homelessness; the method by which eligibility is assessed and by whom; the appeal mechanism available where a patient is refused access; and if she will ma…
855. Deputy Pádraig O'Sullivan asked the Minister for Health the rationale for treating monitored dosage systems, commonly known as blister packs, as a last-resort option under the GMS medicines optimisation support service which commenced on 1 June 2026; her response to concerns that patients in residential care settings will no longer receive blister packs free of charge; the assessment her Department has carried o…
856. Deputy Pádraig O'Sullivan asked the Minister for Health whether patients in receipt of free phased dispensing or blister packs in August 2025 will retain that support indefinitely under the GMS medicines optimisation support service; the arrangements for new patients who would previously have qualified; and if she will make a statement on the matter. [53329/26]
857. Deputy Pádraig O'Sullivan asked the Minister for Health the number of community pharmacies onboarded to date to the national unused medicines return and disposal scheme provided for under the Community Pharmacy Agreement 2025; the target date for all pharmacies to be participating; and if she will make a statement on the matter. [53333/26]
858. Deputy Pádraig O'Sullivan asked the Minister for Health the reason Ireland did not operate a national collection system for unused medicines despite the obligation under Directive 2004/27/EC, in place since 2004; the steps taken to ensure the new scheme achieves full compliance with that Directive; and if she will make a statement on the matter. [53334/26]
859. Deputy Pádraig O'Sullivan asked the Minister for Health when the planned public awareness campaign on the return of unused medicines to pharmacies will launch; the budget allocated to that campaign; and if she will make a statement on the matter. [53335/26]
860. Deputy Pádraig O'Sullivan asked the Minister for Health whether the review of the national unused medicines return and disposal scheme scheduled after nine months of operation will be published; the metrics that will be used to evaluate the scheme, including tonnage of medicines collected and pharmacy participation rates; and if she will make a statement on the matter. [53336/26]
861. Deputy Pádraig O'Sullivan asked the Minister for Health the assessment her Department has made of the contribution of unused medicines in the home to accidental poisoning of children, self-harm and suicide risk; whether data on hospital presentations linked to accidental ingestion of medicines by children will be used to evaluate the impact of the national unused medicines return scheme; and if she will make a s…
485. Deputy Pádraig O'Sullivan asked the Minister for Health whether the medicine belzutifan (welireg) is available for the treatment of patients with Von Hippel-Lindau disease in Ireland; whether it is eligible for reimbursement by the HSE; and if she will make a statement on the matter. [46535/26]
486. Deputy Pádraig O'Sullivan asked the Minister for Health whether the medicine daraxonrasib is available for the treatment of patients with pancreatic cancer in Ireland; whether it is or will be eligible for reimbursement by the HSE; and if she will make a statement on the matter. [46536/26]
2113. Deputy Pádraig O'Sullivan asked the Minister for Health if considering a policy under the Health (Pricing and Supply of Medical Goods) Act 2013 to qualify parallel imported medicines for reimbursement in Ireland at the same reference price as equivalent medicines supplied through the distribution channels of their original manufacturers; and if she will make a statement on the matter. [42753/26]
2255. Deputy Pádraig O'Sullivan asked the Minister for Health if she is aware that according to a survey published by an organisation (details supplied) in May 2026, only 27% of orphan medicines for rare diseases approved between 2021 and 2024 were available to patients in Ireland as of January 2026, compared to an EU average of 43%; the steps being taken to improve access to orphan medicines for patients with rare d…
2256. Deputy Pádraig O'Sullivan asked the Minister for Health if she is aware that according to a survey published by an organisation (details supplied) in May 2026, patients in Ireland wait on average approximately 801 days for access to orphan medicines for rare diseases, compared to an EU average of 614 days; the measures being taken to reduce this waiting time; and if she will make a statement on the matter. [434…
2257. Deputy Pádraig O'Sullivan asked the Minister for Health the specific provisions of the Framework Agreement on the Supply and Pricing of Medicines agreed in March 2026 that will address the finding in a survey (details supplied) that Ireland has an orphan medicine availability rate of 27% against an EU average of 43%; and if she will make a statement on the matter. [43429/26]
2266. Deputy Pádraig O'Sullivan asked the Minister for Health the number of patients receiving standard oral nutritional supplements reimbursed under the community drug schemes, broken down by those receiving first-line products on List A and those receiving non first-line products on List B, in tabular form; and if she will make a statement on the matter. [43512/26]
2267. Deputy Pádraig O'Sullivan asked the Minister for Health if she is satisfied that the categorisation of standard oral nutritional supplements into List A first-line products and List B non first-line products under the Standard Oral Nutritional Supplements First-line Prescribing List for Adults Living in the Community 2019 remains clinically appropriate; whether that list has been reviewed since its introduction…
2268. Deputy Pádraig O'Sullivan asked the Minister for Health the total expenditure by the Health Service Executive on standard oral nutritional supplements reimbursed under the community drug schemes in each year since 2021, in tabular form; and if she will make a statement on the matter. [43514/26]